RVL Pharmaceuticals plc (RVLP)
| Market Cap | 114.46M |
| Revenue (ttm) | 38.01M |
| Net Income (ttm) | -62.13M |
| Shares Out | 83.55M |
| EPS (ttm) | -0.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 45,446 |
| Open | 1.38 |
| Previous Close | 1.38 |
| Day's Range | 1.37 - 1.39 |
| 52-Week Range | 0.98 - 4.85 |
| Beta | 1.54 |
| Analysts | Buy |
| Price Target | 5.30 (+286.9%) |
| Earnings Date | May 12, 2022 |
About RVLP
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed i...
Financial Performance
In 2021, RVLP's revenue was $17.50 million, a decrease of -36.96% compared to the previous year's $27.76 million. Losses were -$64.92 million, -18.43% less than in 2020.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for RVLP stock is "Buy." The 12-month stock price forecast is 5.3, which is an increase of 286.86% from the latest price.
News
RVL Pharmaceuticals plc to Present at Upcoming Conferences
BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Execut...
RVL Pharmaceuticals PLC (RVLP) Reports Q1 Loss, Tops Revenue Estimates
RVL Pharmaceuticals PLC (RVLP) delivered earnings and revenue surprises of 48% and 197.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
RVL Pharmaceuticals plc Reports First Quarter 2022 Financial Results; Provides Commercial Update
First quarter 2022 UPNEEQ net product sales of $5.9 million; 90% growth over fourth quarter 2021
UPNEEQ® Wins Best Professional-Treatment Product by Shape Magazine in the 2022 "Shape Healthy Skin Awards"
BRIDGEWATER, N.J. , May 9, 2022 /PRNewswire/ -- RVL Pharmaceuticals plc (Nasdaq: RVLP) ("RVL" or the "Company") announced today that its FDA approved ptosis drug Upneeq® (oxymetazoline hydrochloride oph...
RVL Pharmaceuticals plc to Discuss First Quarter 2022 Financial Results and Provide Commercial Update
Conference call to be held Thursday, May 12, 2022, at 8:30 a.m. ET Conference call to be held Thursday, May 12, 2022, at 8:30 a.m. ET
UPNEEQ® Wins "Best in Innovation" Award from New Beauty
12th Annual Beauty Awards Selected from over 10,000 Entrants BRIDGEWATER, N.J. , April 6, 2022 /PRNewswire/ -- RVL Pharmaceuticals plc (Nasdaq: RVLP) announced today that its U.S. FDA approved acquired ...
RVL Pharmaceuticals plc Announces Preliminary First Quarter 2022 UPNEEQ® Net Product Sales Results
-- Expects first quarter 2022 preliminary UPNEEQ net product sales of approximately $5.9 million, representing an increase of 90% from the fourth quarter 2021 -- -- Reaffirms fourth quarter 2022 guidanc...
RVL Pharmaceuticals PLC (RVLP) Reports Q4 Loss, Misses Revenue Estimates
RVL Pharmaceuticals PLC (RVLP) delivered earnings and revenue surprises of 10.34% and 7.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
RVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Preliminary First Quart...
Fourth quarter 2021 UPNEEQ product sales of $3.1 million, representing 39% growth over third quarter sales
RVL Pharmaceuticals plc to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide First Quarter 2022...
-- Conference call to be held March 30, 2022, at 4:30 p.m. ET -- -- Conference call to be held March 30, 2022, at 4:30 p.m. ET --
RVL Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2022
BRIDGEWATER, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Exec...
UPDATE – Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “...
-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarter 2022 net sales for UPNEEQ targeted to range from $20-$25 mil...
Osmotica Pharma Announces Rebranding As RVL Pharma, Issues Q4 Sales Outlook
Osmotica Pharmaceuticals plc (NASDAQ: OSMT) will change its name to RVL Pharmaceuticals plc and start trading under the new ticker (NASDAQ: RVLP). The Company says that the rebranding reflects RVL's str...
Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Pl...
-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarter 2022 net sales for UPNEEQ targeted to range from $20-$25 mil...
RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022
-- Topics include corporate name change, launch plans into the medical aesthetics market and general business updates -- -- Featured speakers include Dr. Jackie Yee and Dr. Justin Harper --
Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022
BRIDGEWATER, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, C...
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference
BRIDGEWATER, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, C...
Osmotica Pharmaceuticals (OSMT) Reports Q3 Loss, Misses Revenue Estimates
Osmotica Pharmaceuticals (OSMT) delivered earnings and revenue surprises of -16.67% and -7.96%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s...
Osmotica Pharmaceuticals plc Reports Third Quarter 2021 Results and Provides Business Update
Third quarter Upneeq® product sales of $2.2 million, representing 47% growth over second quarter sales
Osmotica Pharmaceuticals plc to Present at Jefferies London Virtual Healthcare Conference 2021
BRIDGEWATER, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, C...
Osmotica Pharmaceuticals plc to Provide Third Quarter 2021 Business and Financial Update on November 15, 2021
BRIDGEWATER, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that the Company will ...
Analysts Estimate Osmotica Pharmaceuticals (OSMT) to Report a Decline in Earnings: What to Look Out for
Osmotica Pharmaceuticals (OSMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Osmotica Pharmaceuticals plc Announces Closing of $35 Million Underwritten Public Offering
BRIDGEWATER, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that on October 12, 20...
Here's why Osmotica Pharmaceuticals is down 35% on Thursday
Shares of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) tanked more than 35% on Thursday as the company priced its underwritten public offering of 14 million ordinary shares at a discount. Osmotica to gen...
Osmotica Pharmaceuticals plc Announces Debt Financing from Athyrium Capital Management of up to $100 Million
BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has entered in...